BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellectricon Launches Outsourced Discovery Services to Enhance Research Into Cytoskeletal Disturbances


4/4/2013 10:25:47 AM

Mölndal, Sweden – 04 April 2013 – Cellectricon, a leading provider of advanced cell-based screening technologies, today announced the launch of its Discovery Services division. The new services offer pharma/biotech companies and CROs cutting-edge phenotypic screening support, accelerating drug discovery and cell-based assay research into cytoskeletal disturbances – especially for chronic pain.

Cellectricon’s Discovery Services aim to help drug discovery teams shorten lead development times and reduce costs. With leading expertize in assay development and screening, Cellectricon’s Discovery Services team provides fully collaborative support, tailored to each individual study. The entire services process is highly interactive, and guarantees all partners are well informed via frequent reports on assay performance, observations and progress, to ensure project goals are fully realized.

Announcing the new offering, Dr Paul Karila, Head of Cellectricon’s Discovery Services, said: “Our Cellaxess Elektra discovery platform is ideal for compound profiling in excitable primary cells and native tissue using transfection and specific electric field stimulation (EFS). With our platform, we can help researchers identify phenotypic effects in highly relevant biological models early enough in a project’s lifecycle to add real value to the decision of whether to pursue or eliminate a compound, which translates to considerable cost savings in the drug development business.”

For more information on Cellectricon’s Discovery Services and how the new services can benefit your research, visit www.cellectricon.com/discovery-services

About Cellectricon

Cellectricon is a leading provider of advanced cell-based screening technologies and services to accelerate drug discovery and cell-based assay research. Our proprietary technologies include leading systems for high resolution ion-channel screening and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess® Technology enables scalable field stimulation, compound delivery and transfection for genomic screening of primary cells, neurones and stem cells. The Dynaflow® Technology advances ion channel research and discovery applications.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES